AbbVie Inc. $ABBV Shares Sold by Davidson Trust Co.

Key Points

• Davidson Trust Co. reduced its AbbVie stake by 12.5% in the third quarter, selling 4,252 shares and retaining 29,634 shares worth approximately $7.75 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie reported quarterly EPS of $3.65 and revenue of $16.99 billion, exceeding analyst estimates, while revenue rose 10.2% year over year as newer products offset declining Humira sales.
• The company declared a quarterly dividend of $1.73 per share, equivalent to a 2.5% annualized yield. Analysts maintain a generally positive outlook, with AbbVie carrying a “Moderate Buy” consensus rating and an average price target of $277.18.

Davidson Trust Co. lowered its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 12.5% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 29,634 shares of the company's stock after selling 4,252 shares during the period. AbbVie makes up approximately 3.0% of Davidson Trust Co.'s holdings, making the stock its 4th biggest position. Davidson Trust Co.'s holdings in AbbVie were worth $7,752,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Corient Private Wealth LP bought a new position in AbbVie during the second quarter valued at approximately $559,736,000. Legal & General Group Plc bought a new stake in AbbVie in the 2nd quarter worth approximately $2,905,952,000. Jupiter Topco LLC purchased a new stake in AbbVie during the 2nd quarter valued at $1,560,354,000. Cardano Risk Management B.V. raised its stake in AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock valued at $1,244,112,000 after buying an additional 4,908,260 shares during the last quarter. Finally, Diamant Asset Management Inc. lifted its holdings in shares of AbbVie by 21,649.0% during the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company's stock valued at $798,456,000 after buying an additional 3,654,351 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is owned by insiders.

AbbVie Price Performance

Shares of NYSE:ABBV opened at $276.24 on Friday. The company has a market capitalization of $488.06 billion, a P/E ratio of 78.03, a P/E/G ratio of 1.24 and a beta of 0.24. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $277.60. The firm's 50 day simple moving average is $259.06 and its two-hundred day simple moving average is $236.63.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. During the same period in the prior year, the company posted $2.97 earnings per share. The company's revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 13.97 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.5%. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

Wall Street Analyst Weigh In

Several analysts recently commented on ABBV shares. Barclays lifted their price objective on AbbVie from $275.00 to $300.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Scotiabank raised their target price on AbbVie from $280.00 to $320.00 and gave the stock an "outperform" rating in a research report on Tuesday. UBS Group boosted their price target on AbbVie from $260.00 to $275.00 and gave the company a "neutral" rating in a research note on Tuesday. Guggenheim reiterated a "buy" rating and issued a $288.00 price objective on shares of AbbVie in a research note on Friday. Finally, Erste Group Bank raised shares of AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and an average target price of $277.18.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations strengthen AbbVie’s oncology pipeline. The FDA granted two Breakthrough Therapy designations to Temab-A (telisotuzumab adizutecan) for colorectal cancer and non-small cell lung cancer. The designation can accelerate development and regulatory review, although it does not guarantee approval or commercial success. AbbVie’s Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer
• Positive Sentiment: Analysts raised their valuation targets. JPMorgan increased its target to $300 and maintained an overweight rating, while Cantor Fitzgerald lifted its target to $290 and Guggenheim reaffirmed a buy rating with a $288 target. These actions suggest analysts see additional upside from AbbVie’s growth products and pipeline. Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants
• Positive Sentiment: New products are more than offsetting Humira’s patent-loss decline. Humira revenue fell 35.9% to $756 million, but total quarterly revenue rose 10.2% to $16.99 billion. The performance indicates that immunology, neuroscience and other newer medicines are successfully replacing the former blockbuster. AbbVie Outgrew Humira’s Collapse
• Neutral Sentiment: Valuation and income appeal remain part of the debate. AbbVie’s dividend and defensive characteristics may attract income-focused investors, but the stock’s elevated valuation means continued earnings and pipeline execution are important to justify further gains. Treasury Bills or Dividend Stocks

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.